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Change in Use of Sleep Medications After Gastric Bypass
Surgery or Intensive Lifestyle Treatment in Adults with Obesity
Winda L. Ng1,2,3,4, Anna Peeters3,4, Ingmar N€aslund5, Johan Ottosson5, Kari Johansson1, Claude Marcus6,
Jonathan E. Shaw 2,4, Gustaf Bruze1, Johan Sundstr€om7, and Martin Neovius1
Objective: To examine the change in use of hypnotics and/or sedatives after gastric bypass surgery or
intensive lifestyle modification in adults with obesity.
Methods: Adults with obesity who underwent gastric bypass surgery or initiated intensive lifestyle modifi-
cation between 2007 and 2012 were identified through the Scandinavian Obesity Surgery Registry and a
Swedish commercial weight loss database. The two cohorts were matched on BMI, age, sex, education,
history of hypnotics and/or sedatives use, and treatment year (surgery n5 20,626; lifestyle n511,973;
77% women, mean age 41 years, mean BMI 41 kg/m2). The proportion of participants with filled hyp-
notics and/or sedatives prescriptions was compared yearly for 3 years.
Results: In the matched treatment cohorts, 4% had filled prescriptions for hypnotics and/or sedatives
during the year before treatment. At 1 year follow-up, following an average weight loss of 37 kg and 18
kg in the surgery and intensive lifestyle cohorts, respectively, this proportion had increased to 7% in the
surgery cohort but remained at 4% in the intensive lifestyle cohort (risk ratio 1.7; 95% CI: 1.4-2.1); at 2
years, the proportion had increased to 11% versus 5% (risk ratio 2.0; 95% CI: 1.7-2.4); and at 3 years, it
had increased to 14% versus 6% (risk ratio 2.2; 95% CI: 1.9-2.6).
Conclusions: Gastric bypass surgery was associated with increased use of hypnotics and/or sedatives
compared with intensive lifestyle modification.
Obesity (2017) 25, 1451-1459. doi:10.1002/oby.21908
Introduction
Between 1980 and 2014, the worldwide prevalence of obesity
increased rapidly to 10.8% in men and 14.9% in women and in
Sweden to 21.4% in men and 18.6% in women (1). The correspond-
ing prevalences for class III obesity (BMI 40 kg/m2) were 0.6%,
1.6%, 0.9%, and 1.5%, respectively (1). This is concerning because
obesity affects various aspects of health (2), including sleep (3).
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Original Article
EPIDEMIOLOGY/GENETICS
Obesity
Obesity has been associated with sleep disorders such as obstructive
sleep apnea, insomnia, and restless leg syndrome (3). Perhaps as a
consequence, individuals with obesity have also been found to use
more hypnotics and/or sedatives than individuals without obesity
(4). Weight loss interventions have been shown to improve a range
of sleep parameters, mostly those associated with obstructive sleep
apnea (5,6), but their effect on use of hypnotics and sedatives is
unclear. This is an important area to address, as use of hypnotics
and sedatives has been associated with vehicle accidents (7), fall-
related injuries (8), cognitive decline (9), and mortality (10).
Using Swedish nationwide and virtually complete registers, we
aimed to assess the effect of weight loss through gastric bypass sur-
gery versus intensive lifestyle modification on use of hypnotics and/
or sedatives in adults with obesity. We hypothesized that the use of
hypnotics and sedatives would decrease following weight loss due to
improvements in obesity-related sleep disorders and to a greater
degree after gastric bypass surgery than intensive lifestyle modifica-
tion, due to the higher magnitude of weight loss after surgery.
Methods
This study included individuals from the Scandinavian Obesity Sur-
gery Registry (SOReg), which is a nationwide prospective registry
of bariatric surgery patients, and the Itrim Health Database, which is
a registry of individuals who underwent weight loss through a low-
or very-low-calorie diet (LCD/VLCD) with lifestyle modification
(11-14). Individuals were linked to the nationwide Swedish Pre-
scribed Drug Register, health registers at the National Board of
Health and Welfare, and Statistics Sweden using the Swedish perso-
nal identity number, a unique identifier for each Swedish resident.
All analyses were conducted on deidentified data, and the study was
approved by the regional ethics review board in Stockholm, Sweden.
Participants were given the option to opt out of the registries.
Data sources
SOReg. SOReg is a nationwide registry for patients who undergo
bariatric surgery in Sweden (13). It is currently estimated to cover
approximately 99% of all bariatric surgeries, including both public
and private provision. Data on various health factors, including BMI,
are collected as part of clinical practice and recorded electronically.
The Itrim Health Database. The Itrim Health Database contains
health information on participants of a commercially available inten-
sive lifestyle modification program in Sweden. Baseline and quarterly
follow-up data on various health factors, including BMI, were col-
lected from 35 Itrim centers across Sweden, utilizing the same infor-
mation technology platform.
The Prescribed Drug Register. The Prescribed Drug Register
records all filled prescriptions in Sweden. It contains detailed
individual-level information on the date, type, and amount of pre-
scriptions filled. We accessed data on prescriptions registered
between July 1, 2005, and September 30, 2015.
Other registers. Data on age, sex, education, and emigrations
were collected for each individual from the Longitudinal Integration
Database for Health Insurance and Labor Market Studies, the Educa-
tion Register, and the Total Population Register (15) at Statistics
Sweden. Data on hospital visits and deaths were available through
linkage with the National Patient Register and the Causes of Death
Register at the National Board of Health and Welfare.
Inclusion and exclusion criteria
We restricted the study population to individuals who were at least
18 years old, with a BMI between 30 and 50 kg/m2 at the start of
treatment. SOReg patients undertaking nongastric bypass surgery
were excluded (2%). As we required each individual to have pre-
scription data from 2 years prior to 3 years after initiation of treat-
ment, we restricted the study population to those who initiated treat-
ment between July 1, 2007, and September 30, 2012. Individuals
who emigrated after treatment initiation were excluded from the
study (SOReg: n5 126, Itrim: n5 54).
Matching
Individuals from SOReg and Itrim were matched on treatment year
and the set of covariates identified through a directed acyclic graph
(Supporting Information Figure S1) (16) built using DAGitty v.2.3
(DAGitty software, Utrecht, Netherlands) (17). The minimal suffi-
cient adjustment set for producing an unbiased estimate of the total
effect of bariatric surgery on sleep problems included age, sex, soci-
oeconomic status, baseline BMI, and sleep problems prior to treat-
ment. We used data on education levels as a proxy for socioeco-
nomic status (18).
Coarsened exact matching techniques were used, which involves cat-
egorizing values of each matching factor into substantively meaning-
ful groups (Supporting Information Table S1) upon which exact
matching was then performed (19). To minimize loss of information,
we allowed matching strata to include different numbers of surgery
patients and intensive lifestyle modification participants.
Exposures
Patients in the surgery cohort (from SOReg) underwent gastric
bypass. Participants in the intensive lifestyle treatment cohort (from
Itrim) underwent a 3-month dietary weight loss phase facilitated by
LCD or VLCD, followed by a 9-month weight maintenance phase
(Supporting Information Methods S1) (11). The choice of LCD or
VLCD was based on the participants’ baseline BMI, personal prefer-
ence, and contraindication status. Treatment with LCD/VLCD pro-
duces a greater degree of weight loss than other nonsurgical treat-
ments (11,20) and was selected as the comparator cohort due to
presence of obesity and intention to lose weight.
Outcome and follow-up
The main outcome was hypnotics and/or sedatives prescriptions fill-
ing, identified via the nationwide Prescribed Drug Register through
the World Health Organization Anatomical Therapeutic Chemical
(ATC) codes under N05C (Supporting Information Table S2). Medi-
cations were excluded if their primary indication included health
conditions other than sleep problems, such as mental health disor-
ders (clomethiazole [N05CM02] and Valerianae radix [N05CM09]).
Midazolam (N05CD08) was excluded as it is indicated for preopera-
tive sedation. Collectively, the excluded medications constituted
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0.26% of all sleep medication prescriptions in the matched data set
throughout the entire study period.
The categorical outcome was defined as the proportion of individu-
als with at least one filled prescription of the selected medications
in a given year. The continuous outcome was defined as annual
mean treatment dose of hypnotics and/or sedatives, calculated as
follows:
ðNumber of pills filled in a yearÞ 3 ðdose per pill filledÞ
defined daily doses
where defined daily doses (DDDs) refers to the daily dose of a par-
ticular medication recommended by the World Health Organization
(21).
Individuals were followed from treatment initiation until death or
end of follow-up, whichever came first. All individuals in the cur-
rent data set had at least 3 years follow-up. We also created a sec-
ond matched data set composed of the subgroup of individuals with
5 years follow-up.
Covariates
Baseline weight and height measurements were used to calculate
BMI. Poor mental health was defined as a history of inpatient stays
or outpatient visits for psychiatric disorders (ICD10: F00-F99) and/
or prescribed medications for mental health disorders (ATC codes:
N06, N05A, and N05B). In the surgery cohort, information on use
of continuous positive airway pressure (CPAP) was obtained during
clinical examination at baseline. History of inpatient stays and out-
patient visits for any cause were identified through the National
Patient Register, and prescription history was identified from the
Prescribed Drug Register.
Statistical analysis
We compared the proportion of individuals with filled hypnotics
and/or sedatives prescriptions post treatment in the surgery and
intensive lifestyle cohorts using a generalized linear model with log
link, assuming a binomial distribution (or Poisson in the event of
nonconvergence). Analyses were also performed using linear regres-
sion to estimate the mean between-cohort difference in annual treat-
ment dose in individuals with filled hypnotic and/or sedative pre-
scriptions prior to treatment. All analyses were weighted to take into
account the different sizes of matching strata.
Subgroup analysis. Subgroup analyses and treatment interaction
tests were performed by baseline age, sex, education level, BMI,
and mental health status.
Within-group analysis. To assess dose-response relationship
between BMI change and outcomes, we repeated the analyses com-
paring outcomes by tertiles of 1-year %BMI change separately for
the surgery and the intensive lifestyle cohorts. In the surgery cohort,
we also investigated the outcome in patients with versus without
CPAP at baseline (CPAP use data were not available in the inten-
sive lifestyle cohort).
Sensitivity analysis. We repeated the main analysis in the
matched data set, additionally adjusting for the original matching
variables (continuous age, continuous BMI, cumulative DDDs within
2 years prior to treatment, and treatment year), indicators of poor
mental health, and history of health care contacts from 1 year to 2
years prior to treatment (measured through history of inpatient stays,
outpatient visits, and filled prescription for any medications). Health
care contacts in the year immediately prior to treatment (from 0 to 1
year prior to treatment) were not considered because they may be
unusually high during that year, especially in the surgery cohort.
All analyses were performed using SAS version 9.4 (SAS Institute,
Cary, North Carolina) and Stata version 14 (StataCorp, College Sta-
tion, Texas). A statistically significant finding was defined as a two-
sided P value of< 0.05.
Results
Study population
Before matching, there were 24,291 individuals in the surgery cohort
and 13,095 individuals in the intensive lifestyle treatment cohort.
After matching, the numbers were 20,626 (85% of the starting sam-
ple) and 11,973 (91% of the starting sample), respectively (Support-
ing Information Figure S2).
Baseline characteristics
Before matching, surgery patients were more likely to be younger,
have lower education, have higher BMI, and have filled hypnotics
and/or sedatives prescriptions than intensive lifestyle participants.
After matching, discrepancies across treatment cohorts were no lon-
ger detected, except for BMI, which remained 0.5 kg/m2 (95% CI:
0.4-0.6; P< 0.001) higher in the surgery than the intensive lifestyle
cohort (Table 1). In the matched sample, surgery patients were also
more likely to have poor mental health and to have had health care
contacts prior to treatment compared with the intensive lifestyle
participants.
Weight loss and hypnotics and/or sedatives use
after surgery and intensive lifestyle modification
The mean 1-year weight loss was 37 kg in the surgery and 18 kg in
the intensive lifestyle cohort (mean difference 19 kg, 95% CI: 18-
20; P< 0.001). The three most commonly prescribed hypnotics and
sedatives were zopiclone, zolpidem, and propiomazine, accounting
for 96% of all prescriptions in both treatment cohorts throughout the
study period (Supporting Information Table S2 and Supporting
Information Figure S3).
During follow-up, the risk of having filled hypnotics and/or seda-
tives prescriptions was higher in the surgery than the intensive life-
style cohort, and the risk ratio increased with longer follow-up,
peaking at 3 years (risk ratio 2.2, 95% CI: 1.9-2.6; P< 0.001; Figure
1). In the second matched data set, the proportion continued to
increase for up to 5 years of follow-up (Figure 1).
Among those with filled hypnotics and/or sedatives prescriptions
prior to treatment, mean treatment dose increased more in the sur-
gery than the intensive lifestyle cohort, with a mean difference at 3
years of 57 DDDs (95% CI: 39-75; P< 0.001; Figure 2). In the sec-
ond matched data set, the mean difference continued to increase for
up to 5 years of follow-up (Figure 2).
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Adjustment for the original matching variables prior to categorization
(Supporting Information Table S1) and/or indicators of poor mental
health and/or history of health care contacts before treatment resulted
in 0.2 change for risk ratios and 2 DDD change for mean differ-
ences, which remained statistically significant at all time points.
Subgroup analyses
In 12 out of 14 subgroups investigated, surgery patients were at
greater risk of having filled hypnotics and/or sedatives prescriptions
than intensive lifestyle participants during follow-up (Figure 3).
Within each level of educational attainment, the risk was increased
in the surgery compared to the intensive lifestyle cohort. We found
a statistically significant interaction by baseline BMI, but there was
no clear dose-response relationship.
In individuals with filled hypnotics and/or sedatives prescriptions
prior to baseline, we did not find any treatment-subgroup interac-
tions regarding dose, potentially due to low power (Figure 3).
Within-group analyses
Percent BMI change. No dose-response relationship was found
for 1-year %BMI change and the outcome in either the surgery or
the intensive lifestyle cohort (Figure 4).
Baseline use of CPAP (surgery only). The risk of having filled
hypnotics and/or sedatives prescriptions 3 years after treatment did not
differ by baseline use of CPAP. Among those with filled hypnotics and/
or sedatives prescriptions at baseline, mean treatment dose increased
more in patients without than with CPAP at baseline (Figure 4).
Figure 1 Proportion of patients with filled hypnotics and/or sedatives prescriptions in the matched study population with 3 years of follow-
up (upper panel) and in the subgroup with 5 years of follow-up (lower panel). Risk ratios (95% CI) apply to the between-cohort differences
at each follow-up time point. Baseline characteristics of subgroups with 5 years of follow-up are shown in Supporting Information Table
S3. The proportion of patients with filled hypnotics and/or sedatives prescriptions in the unmatched study population is shown in Sup-
porting Information Figure S4. [Color figure can be viewed at wileyonlinelibrary.com]
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Discussion
We found higher use of hypnotics and/or sedatives following gastric
bypass compared with intensive lifestyle modification at 3- and
5-year follow-ups, and this difference was present in 12 out of 14
subgroups investigated. There was no evidence in either treatment
cohort for a dose-response relationship between %BMI change at
1 year and change in use of hypnotics and/or sedatives at 3 years.
Our finding of an increased use of hypnotics and/or sedatives after
gastric bypass is consistent with that from an uncontrolled 2-year
follow-up study of 165 Norwegian patients (22) and from a Swedish
study comparing 3,139 gastric bypass patients with 31,390 general
population controls over 4 years of follow-up (23). Note that the
Swedish study did not match for baseline BMI.
Because we did not find evidence for a dose-response relationship
between %BMI change and change in use of hypnotics and/or seda-
tives, nor any change after substantial nonsurgically induced weight
loss, it is likely that the increased use was driven by the undertaking
of gastric bypass surgery and not by weight loss per se. While we
cannot identify the cause of this phenomenon through our study, a
number of plausible explanations can be identified in the literature.
One possibility is “addiction transfer,” whereby patients stop over-
eating for anxiety relief but acquire other compulsive disorders such
as alcoholism or substance abuse after bariatric surgery (24). The
mechanism is unclear, and whether compulsive eating behavior prior
to surgery can be considered as addiction remains debatable (25),
but this phenomenon is continually being reported in bariatric sur-
gery patients (24). One way to test this hypothesis is through a sub-
group analysis by baseline mental health status. In this study, there
Figure 2 Mean treatment dose among those with filled hypnotics and/or sedatives prescriptions at 1 and/or 2 years prior to treatment, in
the matched study population with 3 years of follow-up (upper panel) and in the subgroup with 5 years of follow-up (lower panel). Error
bars are 95% CI. Mean differences (95% CI) apply to the between-cohort differences at each follow-up time point. Baseline characteris-
tics of subgroups with 5 years of follow-up are shown in Supporting Information Table S3. Mean treatment dose among those with filled
hypnotics and/or sedatives prescriptions in the unmatched study population are shown in Supporting Information Figure S5. Abbrevia-
tions: DDDs, defined daily doses. [Color figure can be viewed at wileyonlinelibrary.com]
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was no interaction between treatment cohort and baseline mental
health status; i.e., use of sleep medication during follow-up was
higher in the surgery cohort compared with the intensive lifestyle
cohort, regardless of the baseline mental health status. Perhaps a
more specific marker of poor mental health or addictive behavior is
needed.
Another plausible explanation is that gastric bypass increases the
risk of alcoholism and substance abuse (26-29), which in turn leads
to poor sleep (30,31). Malabsorption after gastric bypass may
explain the increased mean treatment dose among baseline users,
but not the uptake of new users after surgery (32). One could also
argue that hypnotics and/or sedatives use could increase after sur-
gery due to patients having more frequent contact with clinicians at
follow-up than intensive lifestyle participants. However, this is
unlikely to be the full explanation, given the continuous uptake of
new users even at 3 to 5 years follow-up, when health care contacts
for postoperative care have presumably decreased. In addition, we
observed greater dose increases in individuals in the surgery than
the lifestyle cohort, among those using hypnotics and/or sedatives at
baseline, and these individuals already have an established contact
with a physician.
Figure 3 Use of hypnotics and/or sedatives in the two treatment cohorts at 3-year follow-up, stratified by baseline characteristics, categorically in the overall
matched study population (left) and continuously among those with filled hypnotics and/or sedatives prescriptions at 1 and/or 2 years prior to treatment (right).
Abbreviation: DDDs, defined daily doses.
Figure 4 Within-treatment cohort analysis of the relationship of BMI change and of presurgical use of CPAP on the categorical outcome (with filled hypnotics
and/or sedative prescriptions, Yes/No) in the overall matched study population (left) and for the continuous outcome (mean treatment dose, DDDs) among
those with filled hypnotics and/or sedatives prescriptions at 1 and/or 2 years prior to treatment (right). *Adjusted for baseline age, sex, education, and cumula-
tive DDDs prior to treatment. †Poisson distribution assumed. Abbreviations: CPAP, continuous positive airway pressure; DDDs, defined daily doses.
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In the presence of obstructive sleep apnea, most hypnotics and/or seda-
tives are to be used with caution (33,34). It is possible that clinicians
start to prescribe more hypnotics and/or sedatives to treat residual sleep
problems following substantial improvement in severity of obstructive
sleep apnea post bariatric surgery (recently shown in another study
using SOReg data (35)), as use of hypnotics and/or sedatives is no lon-
ger contraindicated. If this was the case, we should observe a greater
increase in hypnotics and sedatives prescription fillings among baseline
CPAP users than in those without CPAP. Instead, we found a lower
mean treatment dose at 3 years after surgery among CPAP users than
in those without CPAP at baseline, although both cohorts increased
their use compared to baseline. Also, at baseline, the use of hypnotics
and/or sedatives did not differ between those with and without CPAP.
It seems that despite published warnings, hypnotics and sedatives are
still often used in patients with CPAP, potentially to aid with sleep and
improve compliance (36-39).
Our study utilized nationwide registry data, which implies minimum
loss to follow-up for the outcome (0.5% due to emigrations), large
sample size, and high generalizability within the Swedish population,
which is predominantly Caucasian. Use of hypnotics and/or sedatives
was assessed through filled prescriptions recorded in the Prescribed
Drug Register, providing better accuracy than self-reported data. We
included participants in an intensive lifestyle modification program as
our comparator cohort, which addressed previous concerns over lack
of studies on bariatric surgery with comparator interventions produc-
ing sufficient weight loss (40). The average magnitude of 1-year
weight loss from the intensive lifestyle cohort in this study (18 kg) is
substantially larger than other conventional treatment comparators in
previous bariatric surgery studies (max 8 kg) (20).
There are several limitations to this study. Even though we mini-
mized the overlap between sleep and mental health problems by
excluding medications with shared indications for mental health
problems, we cannot control the off-label use of the remaining med-
ications, and there is often more than one reason to prescribe a cer-
tain medication. Nevertheless, even if use of hypnotics or sedatives
is not a perfect marker for sleep problems, our finding of increased
hypnotics and sedatives after bariatric surgery remains a clinically
important observation. Also, our estimates were robust to adjust-
ments for baseline mental health.
This study was not a randomized controlled trial and is therefore prone
to confounding. We attempted to minimize confounding by matching
on covariates identified through a directed acyclic graph, but we cannot
prove if our diagram is true and complete. There may be other inherent
(personality) differences between the surgery and intensive lifestyle
treatment cohorts that we do not capture, which may contribute to the
observed differences. For instance, before matching, intensive lifestyle
participants had higher levels of education, likely representing a more
health-conscious population who may be more resistant to pharmaco-
logical aid such as hypnotics or sedatives. In our analysis, we aimed to
capture this difference in health-seeking behavior between the treatment
cohorts by adjusting for history of health care contacts. The estimates
changed by 0.2 for risk ratios and 2 DDDs for mean differences,
but this may not be sufficient. However, surgery increased the risk of
having filled hypnotics and/or sedatives prescriptions compared with
intensive lifestyle in all education level subgroups.
The surgery cohort in our current study only included gastric bypass.
Our results may not be generalizable to other procedure types.
Conclusion
We found that the use of hypnotics and/or sedatives increased fol-
lowing gastric bypass, and the increase continued for up to 5 years.
We saw no change in use of hypnotics and/or sedatives in the inten-
sive lifestyle treatment group. Future studies are needed to identify
the underlying mechanisms and assess whether these results may be
observed after other bariatric or even nonbariatric surgeries. Our
findings indicate the need for sleep medication monitoring and man-
agement following gastric bypass to prevent uptake of new users
and continuous increase in the mean treatment dose of hypnotics
and sedatives after gastric bypass.O
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